Side-by-side comparison of AI visibility scores, market position, and capabilities
Mental health care clinic network with in-network insurance coverage, San Francisco CA, raised $52M+. Hybrid virtual and in-person therapy with major payer contracts.
Octave is a San Francisco, California-based mental health company founded in 2018 that operates a network of mental health clinics offering therapy and psychiatric care with in-network insurance coverage from major carriers. The company has raised over $52 million and has built a hybrid model offering both in-person care at physical clinic locations and virtual therapy, enabling clients to choose the modality that works best for their needs and circumstances.\n\nOctave's business model prioritizes in-network insurance access, negotiating directly with major commercial payers including Blue Cross Blue Shield, Aetna, and Cigna to make therapy financially accessible to patients who have historically faced high out-of-pocket costs or been directed to out-of-network providers. The company handles credentialing, insurance billing, and administrative infrastructure centrally, allowing its therapists and psychiatrists to focus on clinical work rather than paperwork.\n\nThe company has expanded to multiple markets in California and New York, with plans to grow its geographic footprint. Octave serves adults with a range of mental health conditions including anxiety, depression, relationship difficulties, trauma, and life transitions. By offering in-person clinic access alongside telehealth, Octave differentiates from purely virtual mental health platforms and appeals to clients who prefer or require face-to-face care. Octave is part of the emerging category of tech-enabled mental health clinic operators alongside Mindpath Health and Two Chairs.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.